EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peritoneal Carcinomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Arthur Schmidt Strelow, Vitor dos Santos Barbosa, Milena Rizzo, Rafael de Souza Pinto Paiva Diniz, Eduardo Moreschi, Matheus Bovolim Lourenço, Giulia Miquelao Sala, Fernanda Ceron Damiani, João Henrique Pontalti

International Health Sciences Review · 13.11.2026 · 2 (6)

DOI: 10.70164/ihsr.v2i6.270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 13.11.2026. Verfasst von Arthur Schmidt Strelow und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peritoneal carcinomatosis represents a heterogeneous group of malignancies in which local tumor burden, primary-site biology, and systemic disease behavior jointly determine prognosis. This critical narrative review examines the therapeutic contribution of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with particular attention to patient selection and randomized evidence. PubMed/MEDLINE, full reports of pivotal trials, and international consensus documents available through 2026 were examined, prioritizing comparative survival, perioperative harms, and clinical applicability. Complete macroscopic cytoreduction is a central condition for meaningful disease control in suitable patients, but the benefit attributable to HIPEC is not uniform. In colorectal peritoneal metastases, PRODIGE 7 did not establish an overall survival advantage for short-duration oxaliplatin HIPEC, whereas the CAIRO6 trial did not support routine perioperative systemic chemotherapy for all resectable cases. In ovarian cancer, benefit appears most reproducible at interval cytoreduction, with more selective evidence in recurrence. Recent gastric trials found no survival benefit and substantial treatment burden. For pseudomyxoma peritonei and selected peritoneal mesothelioma, spe cialized CRS-HIPEC remains strongly supported by consensus despite low-certainty comparative evidence. Decisions should integrate resectability, disease distribution, expected morbidity, tumor-specific evidence, and patients' priorities.

Zitieren

APA

Strelow, A. S., Barbosa, V. D. S., Rizzo, M., Diniz, R. D. S. P. P., Moreschi, E., Lourenço, M. B., Sala, G. M., Damiani, F. C., & Pontalti, J. H. (2026). Peritoneal Carcinomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. International Health Sciences Review, 2(6). https://doi.org/10.70164/ihsr.v2i6.270

Vancouver

Strelow AS, Barbosa VDS, Rizzo M, Diniz RDSPP, Moreschi E, Lourenço MB, et al. Peritoneal Carcinomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. International Health Sciences Review. 2026;2(6). doi:10.70164/ihsr.v2i6.270

BibTeX
@article{Strelow2026,
  author = {Strelow, Arthur Schmidt and Barbosa, Vitor dos Santos and Rizzo, Milena and Diniz, Rafael de Souza Pinto Paiva and Moreschi, Eduardo and Lourenço, Matheus Bovolim and Sala, Giulia Miquelao and Damiani, Fernanda Ceron and Pontalti, João Henrique},
  title = {Peritoneal Carcinomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy},
  journal = {International Health Sciences Review},
  year = {2026},
  volume = {2},
  number = {6},
  doi = {10.70164/ihsr.v2i6.270}
}
Kostenlos starten →